Identification of lncRNA expression profiles and ceRNA analysis in the spinal cord of morphine-tolerant rats

Jiali Shao, Jian Wang, Jiangju Huang, Chang Liu, Yundan Pan, Qulian Guo and Wangyuan Zou*

Abstract

Morphine tolerance is a challenging clinical problem that limits the use of morphine in pain treatment, but the mechanisms of morphine tolerance remain unclear. Recent research indicates that long noncoding RNAs (lncRNAs) might be a novel and promising target in the pathogeneses of diseases. Therefore, we hypothesized that lncRNAs might play a role in the development of morphine tolerance. Male Sprague-Dawley rats were intrathecally injected with 10 μg morphine twice daily for 7 consecutive days. The animals were then sacrificed for lncRNA microarray tests, and the results were validated by RT-qPCR. Next, functional predictions for the differentially expressed mRNAs (DEmRNAs) were made with the Gene Ontology/Kyoto Encyclopedia of Genes and Genomes (GO/KEGG), and predictions for the differentially expressed lncRNAs (DElncRNAs) were made based on competitive endogenous RNA (ceRNA) analyses. The rats successfully developed morphine tolerance. LncRNA microarray analysis revealed that, according to the criteria of a log2 (fold change) > 1.5 and a P-value < 0.05, 136 lncRNAs and 278 mRNAs were differentially expressed in the morphine tolerance group (MT) compared with the normal saline group (NS). The functions of the DEmRNAs likely involve in the processes of the ion channel transport, pain transmission and immune response. The ceRNA analysis indicated that several possible interacting networks existed, including (MRAK150340, MRAK161211)/miR-219b/Tollip. Further annotations of the potential target mRNAs of the miRNAs according to the gene database suggested that the possible functions of these mRNAs primarily involved the regulation of ubiquitylation, G protein-linked receptors, and Toll-like receptors, which play roles in the development of morphine tolerance. Our findings revealed the profiles of differentially expressed lncRNAs in morphine tolerance conditions, and among these lncRNAs, some DElncRNAs might be new therapeutic targets for morphine tolerance.

Keywords: LncRNA, ceRNA, Morphine tolerance, Spinal cord

Introduction

Morphine tolerance is defined as the diminished analgesic effect and the need for a higher dose to achieve the desired analgesic effect after chronic exposure to morphine [1–4]. Over the past decades, people have attempted to elaborate the mechanisms of morphine tolerance with minimal success. The recent focus of this area is the role of non-coding RNAs (ncRNAs) [5, 6]. Among ncRNAs, some studies have reported that miRNAs are involved in the development of morphine tolerance [7, 8], including the let-7 family, miR-23b [9], miR-133b, miR-339 [10], miR-365 [11] and miR-219-5p [12]. However, the research regarding long non-coding RNAs (lncRNAs) is still in its infancy.

The sequences of lncRNAs range in size from approximately 200 nt to over 100 kb, and lncRNAs can function in novel mechanisms of the modulation of the expression of genes [13, 14]. Over the past decades, lncRNAs have been the highlight of some studies of cancer, osteoarthritis, nervous system function and development [15–17]. In pain research, recent studies have claimed that Knav2 AS [18], uc.48+ [19] and some other lncRNAs [20] might play roles in the process of the development of neuropathic pain [21, 22]. The function of lncRNAs has been illustrated as follows: lncRNAs can interact with miRNAs, bind to transcription factors, modulate chromatin remodeling, and even directly
regulate the functions of target proteins. Among lncRNAs, some may act as competitive endogenous RNAs (ceRNAs) that target miRNAs [14].

The ceRNA hypothesis was proposed in 2011 with the aim of further elaborating the relationships among RNAs. Salmena et al. [23] highlighted that some RNAs act as ceRNAs that participate in mutual competition for common binding sites of target miRNAs and thus modify the functions of the target miRNAs. Recent research has indicated that ceRNA analysis might shed a light on functional predictions of the effects of lncRNAs [24].

Therefore, in the present study, we hypothesized that lncRNAs might be differentially expressed and act in direct or indirect manners during the development of morphine tolerance. To address this hypothesis, we attempted to identify the lncRNA expression profiles in the spinal cords of rats under normal and morphine tolerance conditions and to predict the possible functions of differentially expressed lncRNAs (DElncRNAs).

Methods

Intrathecal injection of morphine induces a chronic morphine tolerance model in rats

Adult male Sprague-Dawley rats (weight 240–260 g) were obtained from the Hunan SJA Laboratory Animal Company (Hunan, China). The rats were housed in groups and maintained on a 12/12 light-dark cycle at a room temperature of 22 ± 1 °C with food and water freely available. The experimental procedures were approved by the Animal Care and Use Committee of Central South University and conducted in strict accordance with the guidelines of the International Association for the Study of Pain [25]. To establish the rat model of morphine tolerance, rats in the morphine tolerance group (MT, n = 8) were intrathecally injected (i.t.) with 10 μg (1 μg/μl) of morphine twice daily at 08:00–09:00 am and 16:00–17:00 pm for 7 consecutive days [3, 26]. The normal saline group (NS, n = 8) was injected with equal volumes of normal saline at the same time points.

Tail flick test

The tail flick test was used to measure thermal sensitivity. Before conducting this test, the rats were placed on the plantar surface for 15 min to adapt to the testing environment. Then, we tested one fixed point of the tail 2–3 cm from the tip using the Hargreaves apparatus (Italy, UGO Basile) [26, 27]. The results are expressed as the tail withdrawal latency (TWL), which was ultimately converted to the percent of the maximum possible effect (%MPE). The radiant index was set at 90, and the cut-off was 20 s to avoid tissue damage. The tests were conducted 30 min before and after the morning injection of morphine on days 1, 3, 5, and 7.

Tissue collection and RNA isolation

On day 8, after the morning injection with morphine or saline, the rats were deeply anesthetized with pentobarbital sodium (1%) one hour later. Then, we decapitated the rats, collected the lumbar enlargements and placed the collected tissues into liquid nitrogen as quickly as possible for preservation. Next, we extracted the total RNA from the spinal tissues and tested the RNA quantity and quality with a NanoDrop ND-1000 Spectrophotometer (Thermo, USA) and tested the RNA integrity with agarose gel electrophoresis (2%). Subsequently, we stored the remnant RNA at −80 °C for later use. The RNA isolation was performed by Kangcheng Bio-tech (Shanghai, China).

Microarray assay

We employed a rat lncRNA microarray 4 × 44 k, V1.0 (Arraystar) containing approximately 9000 lncRNAs to screen the differentially expressed lncRNAs and mRNAs. The total RNAs of the MT and NS groups (n = 5) were hybridized with the gene chips. The RNA samples were transcribed into fluorescent cRNAs along the entire lengths of the transcripts without a 3’ bias utilizing random primers. The labeled cRNAs were hybridized to the rat lncRNA microarray. Next, the arrays were scanned with an Agilent DNA Microarray Scanner (part number G2505C). The array images were analyzed with Agilent Feature Extraction software (version 11.0.1.1). Quantile normalization and subsequent data processing were performed using the GeneSpring GX v12.1 software package (Agilent Technologies, USA). The microarray hybridization was performed by Kangcheng Bio-tech (Shanghai, China).

Bioinformatics analysis

We used the criteria of a log2 (fold-change) > 1.5 and a P-value < 0.05 to screen for the deregulated RNAs. Hierarchical clustering was performed with Cluster 3.0, and the heat maps were generated in Java Treeview. The DElncRNAs were analyzed according to the pathway annotations of the Kyoto Encyclopedia of Genes and Genomes (KEGG) and Gene Ontology (GO) functional enrichment using CapitalBio. The -log10 (P-values) of the GO and pathway results are displayed in the histogram. The DElncRNAs were analyzed by ceRNA analyses, which were conducted with Arraystar’s homemade miRNA target prediction software, which is based on TargetScan and miRanda [28]. A lncRNA/miRNA/mRNA interaction network was generated to visualize the interactions using Cytoscape. The NCBI Database was used to annotate the functions of the potential target genes.
Real-time quantitative polymerase chain reaction (RT-qPCR)

The microarray results were confirmed by RT-qPCR. The total RNAs of the MT and NS groups (\(n = 5\) in each group) were reverse transcribed using random hexamer primers (Arraystar Flash RNA Labeling Kit, Arraystar) according to the manufacturer’s description. The expression levels of 18 lncRNAs (MRAK080737, MRAK159688, MRAK046606, DQ266361, XR_005988, uc.48+,-, uc.310-, XR_009527, XR_008662, S66184, MRAK161211, MRAK150340, XR_006440, AF196267, MRAK077287, MRAK014088, MRAK141001 and MRAK038897), as well as 12 DEmRNAs (S100a8, Batf, Ccl7, RT1-Bb, RatNP-3b, Grm2 and Mmp9, Prrx2, Asb2, Fam111a, Kcnv2 and Tmem119) were examined. GAPDH was used as the house-keeping gene. The sequences of all primers are presented in Table 1. We conducted the RT-qPCR tests with a 10 \(\mu\)L reaction system in a ViiA 7 Real-time qPCR System according to the manufacturer’s protocol. Melting-curve analysis was performed to monitor the specificity of the production. All experiments were replicated three times. The gene expression levels in the MT and NS groups were analyzed with the \(2^{-\Delta\Delta CT}\) method.

Statistical analysis

All data were presented as mean \(\pm\) s.e.m. The statistical significance of differences between groups was analyzed with two-way repeated-measures of ANOVA followed by Bonferroni test or with Student’s \(t\)-test. \(P\) values less than 0.05 were considered statistically significant.

Results

Construction of the rat morphine tolerance model

The tail flick test data revealed that there were no significant changes in the thermal sensitivities of NS group (\(n = 8\) in each group). However, comparisons between the two groups revealed that, on day 1 post-injection, the %MPE of the MT group (\(n = 8\) in each group) was significantly higher than that of the NS group (\(P < 0.05\)). On day 3 post-injection, the %MPE of the MT group began to decline but remained higher than that of the NS group (\(P < 0.05\)). On day 5 post-injection, the %MPEs did not significantly differ between the two groups (\(P > 0.05\)), and this state continued to day 7 (Fig. 1a), which suggested that a stable morphine tolerance model had been established.

Overview of the IncRNA and mRNA expression profiles

First, we created an overview of the IncRNA and mRNA expression profiles using a using scatter plot, which revealed that large numbers of IncRNAs and mRNAs were differentially expressed between the MT and NS groups (\(n = 5\); Fig. 1d). Next, hierarchical cluster analyses of all of the IncRNAs and mRNAs was applied and revealed that the 5 NS and 5 MT samples clustered independently, and the results also indicated high degrees of consistency in both the NS and MT groups (Fig. 1b, c). All of the microarray results have been uploaded to the GEO database (GSE110115).

Differentially expressed lncRNAs and mRNAs in morphine tolerance

According to the criteria of a log2 (fold change) > 1.5 and a \(P\)-value < 0.05, the microarray data identified 136 IncRNAs, including 84 up-regulated and 52 down-regulated IncRNAs, which were significantly altered in the MT group compared with the NS group. The IncRNAs that exhibited the greatest up-regulations were XR_005988, DQ266361, and MRAK046606 with XR_005988 exhibiting the largest up-regulation [log2 (fold change) =12.4243]. The IncRNAs that exhibited the greatest down-regulations were AF196267, XR_009493, and MRAK150340 with AF196267 exhibiting the largest down-regulation [log2 (fold change) =2.2025]. Detailed information, including the top 40 up-regulated and top 40 down-regulated IncRNAs, is provided in Table 2.

Regarding the DEmRNAs, there were 278 genes (176 up-regulated and 102 down-regulated) whose changes met the criteria. These DEmRNAs contained many genes that are known to be involved in pain processing, including Ccl7, Batf, S100a8, Kcnv2, Rgs1, Prrx2, Mmp9, etc. Detailed information about the top 30 up-regulated and top 30 down-regulated mRNAs is listed in Table 3.

Validation of the IncRNA and mRNA expressions

To validate the reliability of the microarray results, 18 DElncRNAs and 12 DEmRNAs were selected and validated by RT-qPCR. The data shown that 11 of 18 selected DElncRNAs (XR_005988, DQ266361, MRAK159688, XR_008662, XR_009527, S66184, MRAK150340, MRAK161211, MRAK038897, AF196267 and MRAK141001) and 7 of 12 selected DEmRNAs (Batf, Ccl7, RatNP-3b, Mmp9, Kcnv2, Tmem119 and Asb2) exhibited the same trends in altered expressions and the same significant differences in the microarray and RT-qPCR analyses. On the other hand, the other altered mRNAs and IncRNAs exhibited the trends in changes, but the differences between the two groups were not significant, possibly due to the small sample size (Fig. 2a, b).

Class distributions of the DElncRNAs

The examined IncRNAs were categorized into five groups according to their associations with coding genes: intergenic IncRNAs, antisense overlap IncRNAs, sense overlap IncRNAs, bidirectional IncRNAs, and other. One of the mechanisms by which IncRNAs act is through the interplay with adjacent coding genes [20, 29]; therefore, it was important to classify the locations of the IncRNAs.
Our data revealed that, among these DElncRNAs, intergenic lncRNAs and sense overlap lncRNAs accounted for the majority, and only five lncRNAs belonged to the bidirectional category. The concrete data are presented in Fig. 2c.

**Functional predictions for the DEMRNAs in the morphine-tolerant rats**

To explore the molecular functions of the DEMRNAs in morphine tolerance conditions, we further performed GO and pathway analyses genes that differentially regulated in the MT and NS groups. The pathway analyses indicated that the most significantly enriched pathways of the up-regulated genes included the TNF metabolic pathway and phagocytic processes, and the down-regulated genes in the MT group were involved in synaptic vesicle activity, the arachidonic acid metabolic pathway, etc. (Fig. 3a, b).

The GO results revealed that the most significantly enriched molecular functions of the up-regulated genes in the MT group were peptidase activity, G-protein-coupled receptor activity, and biological processes concentrated on the cytokine response, defense and the immune response. The cell components primarily belonged to extracellular domains and intercellular domains. The most significantly enriched molecular functions of the down-regulated genes in the MT group were voltage-gated channel activity, ion transmembrane activity, and biological processes concentrated on potassium ion transport. The cell components were associated with the sarcolemma, cytoplasmic membrane, and ion channel complexes (Fig. 3c-h).

**Table 1** The detailed information of primer sequence

| Sequence name | Primer sequence | Amplicon size (bp) |
|---------------|----------------|-------------------|
| GAPDH(RAT)    | F:S’ GCCCTCTGCCTCCCTCGTCTA3’ R:S’ TGGTAACCCGCGCTCCGCTA3’ | 124 |
| MRAK161211    | F:S’ CTGCCACCCAAAGTTTCTAACATC3’ R:S’ TGGAGAGAGGTGGTTCCGAAGTA3’ | 63 |
| MRAK038897    | F:S’ GGTGGTCTTCTCAGGTTGGTTGTTG3’ | 132 |
| MRAK014088    | F:S’ GGTGCTTTCTTCTCGGGTCTGTC3’ | 102 |
| MRAK080737    | F:S’ GGTGACAGCCCAAGTGTA3’ R:S’ GAGACAATAATTGGAGGC3’ | 105 |
| MRAK159688    | F:S’ GGTACTGTGACCTTGCCCTGCC3’ | 78 |
| MRAK046060    | F:S’ GCCGAGACTGCTCTGAGATGAGAGAC3’ | 101 |
| MRAK150340    | F:S’ ACAAGTTGAGGCGACCTGGAC3’ | 205 |
| DQ266361      | F:S’ GTGTGTGTTAATCCCTCATGCCC3’ | 63 |
| XR_006440     | F:S’ GGAGCCATCAATGCTGAAAGC3’ | 162 |
| XR_005988     | F:S’ GTGTGACCTCTCGGACCTGCTT3’ | 101 |
| uc.48+        | F:S’ AATGCGAACATCAGGAGGAG3’ | 279 |
| uc.310-       | F:S’ CTACTACAAAATGACAGCAGA3’ | 128 |
| XR_009527     | F:S’ CCAAGGCCCCGTTTGAGGAT3’ | 116 |
| XR_008662     | F:S’ TAATGAGAGAGATGAGAATGCG3’ | 103 |
| S66184        | F:S’ TCTCACTGACCTACTGCACTH3’ | 51 |
| AF196267      | F:S’ GCCATACAAATTTCTCTGACTG3’ | 135 |
| MRAK077287    | F:S’ GCTTAATATGCTCCACGCAAAA3’ | 151 |
| MRAK141001    | F:S’ CTCCTCTACGCTTACCTTG3’ | 87 |
| S100a8        | F:S’ GGAGAACATCCAGGCCCCTCTA3’ | 168 |
| Batf          | F:S’ GAGGGCCGAGAAGAAAGAGG3’ R:S’ AGCTAGCTAAGGCTCAATGAGA3’ | 87 |
| Ccl7          | F:S’ GGTGGCTTCTTCTCAGGTTGGTTG3’ | 136 |
| RT1-Bb        | F:S’ GCCCTTCACAACCCACCACACTT3’ | 141 |
| Prx2          | F:S’ AGAAGAAAGACGCGCCTGGA3’ R:S’ CAAGGCCGCTCCGAGTAGTG3’ | 97 |
| Asb2          | F:S’ TGGTTTTTCTGCCGTCCTGTTG3’ | 120 |
| RatNP-3b      | F:S’ CATACGCCCAAGAAAGCTCACC3’ | 168 |
| Grm2          | F:S’ CCCGGAGAACCTCCAGGACG3’ | 207 |
DElncRNAs regardless of their adjacent coding genes. According to the ceRNA analysis, we obtained an overview of the potential lncRNA/miRNA/mRNA interactions (Fig. 4a), and we then further identified several promising networks of lncRNA/miRNA/mRNA interactions (Fig. 4b), which included (MRAK161211, MRAK150340)/miR-219b/Tollip and XR_006440/(miR-365, let7)/(Usp31, Usp42, Clcn4) networks, and we used these networks to create functional annotations of the predicted target mRNAs by searching the Gene database. The results indicated that the predicted target mRNAs mainly functioned in the process of ubiquitinylation, the GRCP and TLR signaling pathways, and the modulations of transcription, translation and post-translational modification, and these functions might constitute the foundation of morphine tolerance.

Discussion

In the present study, we detected 136 DElncRNAs and 278 DEmRNAs overall and we found that compared with normal rats, DElncRNAs and DEmRNAs were present in the spinal cords of morphine-tolerant rats; GO and KEGG pathway analyses revealed that the potential functions of the DEmRNAs may be concentrated on the processes that are thought be involved in the formation of morphine tolerance; and the ceRNA analysis identified several potential lncRNA/miRNA/mRNA interaction networks that might modulate the development of morphine tolerance.

To identify as many DElncRNAs and DEmRNAs candidates as possible, we set the criteria at a log2 (fold change) > 1.5 and a P-value < 0.05 [30]. Next, we considered several criteria to select lncRNAs and mRNAs from our microarray data for validation. Firstly, we attempted to select the relevant candidates that might be related to our previous studies of morphine tolerance and miRNAs [11, 12]. Secondly, for validation, we chose the lncRNA candidates that exhibited higher fold changes and greater raw expression intensities and had adjacent mRNA that was related to morphine tolerance.

Among the DElncRNAs that we detected, XR_005988 exhibited the most significant up-regulation and was
Table 2 The detailed information of top 40 up-regulated and 40 down-regulated lncRNAs

| Up-regulated lncRNAs | Fold change(MT/NS) | P-value | Down-regulated lncRNAs | Fold change(MT/NS) | P-value |
|----------------------|--------------------|---------|------------------------|--------------------|---------|
| XR_005988            | 12.34156           | 0.003685| AF196267               | 2.202529           | 0.012181|
| DQ266361             | 2.486278           | 0.000882| XR_009493              | 2.115125           | 0.019025|
| MRAK046606           | 2.367485           | 0.020344| MRAK150340             | 2.060765           | 0.000308|
| uc.167-              | 2.199281           | 0.002987| MRAK037188             | 1.956905           | 0.000066|
| uc.468+              | 2.137996           | 0.000249| XR_006440              | 1.952104           | 0.003301|
| XR_009482            | 2.065426           | 0.022224| AF196206               | 1.938910           | 0.015500|
| AF305713             | 2.052460           | 0.001121| BC126091               | 1.906750           | 0.020304|
| MRAK165072           | 2.020835           | 0.015095| uc.370+                | 1.900405           | 0.000477|
| MRAK159688           | 2.009110           | 0.008496| MRAK156916             | 1.879795           | 0.013478|
| uc.28-               | 1.957873           | 0.033513| XR_008800              | 1.872603           | 0.022847|
| DQ223059             | 1.911577           | 0.043779| MRAK077287             | 1.816863           | 0.000017|
| uc.48+               | 1.897821           | 0.005311| MRAK14088              | 1.773360           | 0.000324|
| XR_006726            | 1.887222           | 0.008923| MRAK161211             | 1.765669           | 0.014718|
| XR_009483            | 1.883345           | 0.020007| BC158785               | 1.742858           | 0.005583|
| MRAK013672           | 1.849562           | 0.027735| MRec009dx              | 1.721422           | 0.014515|
| MRAK018927           | 1.848401           | 0.025469| MRAK135122             | 1.718807           | 0.009117|
| uc.482-              | 1.827252           | 0.000618| MRAK141001             | 1.690469           | 0.000352|
| MRAK138235           | 1.824250           | 0.005928| MRec007nw              | 1.688666           | 0.043028|
| uc.156-              | 1.810205           | 0.037932| uc.264+                | 1.687839           | 0.023742|
| XR_008353            | 1.802395           | 0.008201| EF088428               | 1.673345           | 0.001656|
| uc.462+              | 1.791152           | 0.001958| uc.363+                | 1.672870           | 0.011181|
| MRAK134839           | 1.770980           | 0.033987| BC169026               | 1.665411           | 0.007442|
| MRAK054291           | 1.760502           | 0.037076| MRAK008891             | 1.659204           | 0.018204|
| BC093392             | 1.758918           | 0.030404| MRAK135686             | 1.656007           | 0.005067|
| MRec007cpx           | 1.756746           | 0.023148| MRAK051195             | 1.625373           | 0.000267|
| MRAK050995           | 1.742487           | 0.032134| BC097960               | 1.619298           | 0.003837|
| XR_009527            | 1.742256           | 0.022408| MRAK169397             | 1.617138           | 0.030259|
| uc.395-              | 1.733383           | 0.035051| MRAK046121             | 1.614043           | 0.005023|
| XR_005532            | 1.732123           | 0.042440| MRAK080238             | 1.594013           | 0.008840|
| uc.158-              | 1.723747           | 0.010144| BC061963               | 1.592978           | 0.002208|
| MRec007jeg            | 1.722591          | 0.006501| MRAK13677              | 1.592863           | 0.000261|
| XR_008662            | 1.716865           | 0.020951| XR_009137              | 1.575140           | 0.014863|
| XR_008674            | 1.695926           | 0.047672| BC063733               | 1.561696           | 0.008523|
| S66184               | 1.680145           | 0.026505| MRAK083715             | 1.557152           | 0.004611|
| M81783               | 1.670161           | 0.011349| MRAK038897             | 1.555085           | 0.007252|
| MRAK083472           | 1.662885           | 0.008172| MRAK041309             | 1.554516           | 0.000067|
| XR_009489            | 1.660491           | 0.002989| MRAK147844             | 1.551990           | 0.000730|
| XR_008266            | 1.654757           | 0.012200| MRAK051810             | 1.549681           | 0.022164|
| uc.310-              | 1.653784           | 0.013204| uc.185+                | 1.545991           | 0.024361|
| uc.463-              | 1.651362           | 0.021613| BC079474               | 1.544677           | 0.000147|

classified as a long intergenic non-coding RNA (lincRNA). Although we obtained no information about XR_005988 or its associated genes through searches of all types of gene databases, it is well known that lncRNAs account for the main portion of lncRNAs and exhibit the most substantial biological functions [31], which indicates that XR_005988 is still a promising lncRNA molecule for further study. Additionally, XR_..
Table 3 The detailed information of top 30 up-regulated and 30 down-regulated mRNAs

| Gene symbol | Description                                                                 | Fold change (MT/NS) | P-value     |
|-------------|------------------------------------------------------------------------------|---------------------|-------------|
| **Up-regulated genes**                                                                                   |                     |             |
| RT1-Bb      | RT1 class II, locus Bb                                                       | 26.0600137          | 0.03123893  |
| RatNP-3b    | defensin RatNP-3 precursor                                                   | 4.6945682           | 0.00237615  |
| Lilrb3      | leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains), member 3 | 4.3359795           | 0.00815228  |
| Defa7       | alpha-defensin 7                                                             | 4.2525247           | 0.00156229  |
| Clec9f      | macrophage-inducible C-type lectin                                          | 3.4622832           | 0.01864872  |
| Ccl7        | chemokine (C-C motif) ligand 7                                               | 3.3728046           | 0.01483951  |
| Sele        | selectin, endothelial cell                                                   | 3.3632425           | 0.03028204  |
| Slpi        | secretory leukocyte peptidase inhibitor                                      | 3.2118152           | 0.00024306  |
| Lilrc2      | leukocyte immunoglobulin-like receptor                                       | 3.1471364           | 0.01375120  |
| V1r4        | vomeronasal 1 receptor, J4                                                   | 2.9047312           | 0.03220865  |
| Gja5        | gap junction membrane channel protein alpha 5                               | 2.8707048           | 0.02230140  |
| Mmp9        | matrix metallopeptidase 9                                                    | 2.832538            | 0.02991875  |
| Batf        | basic leucine zipper transcription factor                                    | 2.7432184           | 0.00125327  |
| S100a8      | S100 calcium binding protein A8 (calgranulin A)                             | 2.7009035           | 0.00561932  |
| Birc3       | baculoviral IAP repeat-containing 3                                          | 2.6968995           | 0.01058921  |
| Bd3         | B-cell CLL/lymphoma 3                                                        | 2.6847827           | 0.00419171  |
| Ccr1        | chemokine (C-C motif) receptor 1                                             | 2.5775393           | 0.00007731  |
| Ori463      | olfactory receptor 463 (predicted)                                           | 2.5772986           | 0.01425058  |
| Np4         | defensin NP-4 precursor                                                      | 2.4883044           | 0.00271115  |
| Grm2        | glutamate receptor, metabotropic 2                                           | 2.4429444           | 0.00113554  |
| Sip1l2      | antileukoproteinase-like 2                                                   | 2.4380328           | 0.00066484  |
| Cn1         | calponin 1                                                                  | 2.4269788           | 0.02918594  |
| Ori139      | olfactory receptor Ori139                                                    | 2.4268332           | 0.01332394  |
| Obp3        | alpha-2u globulin PGCL4                                                      | 2.3723118           | 0.03995990  |
| Crisp4      | cysteine-rich secretory protein 4                                            | 2.3633549           | 0.00810051  |
| Ori1454_predicted | olfactory receptor 1454 (predicted)                                    | 2.3350625           | 0.00247670  |
| Napsa       | napsin A aspartic peptidase                                                  | 2.2770041           | 0.00352752  |
| Ori1374_predicted | olfactory receptor 1374 (predicted)                                   | 2.2313479           | 0.00040213  |
| LOC497796   | Ly49 inhibitory receptor-like                                                | 2.2302475           | 0.00022859  |
| Sip1l3      | antileukoproteinase-like 3                                                   | 2.2153032           | 0.00045886  |
| **Down-regulated genes**                                                                             |                     |             |
| Fam111a     | hypothetical protein LOC499322                                               | 5.1287218           | 0.02433528  |
| Kcnv2       | potassium channel, subfamily V, member 2                                     | 2.8837136           | 0.00586212  |
| Fkbp6       | FK506 binding protein 6                                                       | 2.8648794           | 0.00576975  |
| Nlpl10      | "NLR family, pyrin domain containing 10"                                     | 2.6101210           | 0.00386452  |
| Rgs1        | regulator of G-protein signaling 1                                           | 2.4933037           | 0.00327101  |
| Ly49B       | Ly49 inhibitory receptor 8                                                   | 2.3732515           | 0.01051908  |
| Tmem119     | transmembrane protein 119                                                    | 2.3374630           | 0.00064129  |
| Cldn14      | "Rattus norvegicus claudin 14"                                               | 2.3184480           | 0.00751794  |
| Dykr1a      | dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1A            | 2.2472669           | 0.00077705  |
| Ckmt2       | sarcormic mitochondrial creatine kinase                                      | 2.2142101           | 0.00051314  |
| Asb2        | ankyrin repeat and SOCS box-containing protein 2                             | 2.1709796           | 0.00039719  |
| Art2b       | ADP-ribosyltransferase 2b                                                    | 2.1680042           | 0.00124959  |
| LOC498335   | similar to Small inducible cytokine B13 precursor (CXCL13)                   | 2.1501415           | 0.00012158  |
### Table 3 The detailed information of top 30 up-regulated and 30 down-regulated mRNAs (Continued)

| Gene symbol | Description | Fold change (MT/NS) | P-value |
|-------------|-------------|---------------------|---------|
| Prrx2       | paired related homeobox 2 | 2.1294428 | 0.01452534 |
| LOC364773   | aldo-keto reductase family 1, member C12 | 2.1023343 | 0.00302323 |
| Cdkn2b      | cyclin-dependent kinase inhibitor 2B (p15, inhibits CDK4) | 2.0882944 | 0.00336651 |
| Cd22        | CD22 molecule | 2.0855279 | 0.01215534 |
| Nhrc2       | NHL repeat containing 2 | 2.0426710 | 0.00054605 |
| Fcrl5       | Fc receptor-like 5, scavenger receptor | 2.0407116 | 0.00627688 |
| Clica3      | chloride channel calcium activated 3 | 2.0188429 | 0.01580260 |
| Dntt        | deoxynucleotidyltransferase, terminal | 2.0019106 | 0.00547055 |
| Grap2       | GRB2-related adaptor protein 2 | 1.9900082 | 0.00968363 |
| Thrsp       | thyroid hormone responsive protein | 1.9814822 | 0.02740488 |
| Plek2       | pleckstrin 2 | 1.9662998 | 0.00879852 |
| Alox12      | arachidonate 12-lipoxygenase | 1.9121487 | 0.00631083 |
| Trnfsf4     | tumor necrosis factor (ligand) superfamily, member 4 | 1.8804698 | 0.00229007 |
| Mpz12       | myelin protein zero-like 2 | 1.8783013 | 0.0003750 |
| Prkag3      | protein kinase, AMP-activated, gamma 3 | 1.8643095 | 0.00970172 |
| Nr0b2       | nuclear receptor subfamily 0, group B, member 2 | 1.8348501 | 0.00251892 |
| Traf3p3     | TRAF3 interacting protein 3 | 1.8326037 | 0.02787730 |

**Fig. 2** RT-qPCR validation of eighteen deregulated lncRNAs (a) and twelve deregulated mRNAs (b) in the lumbar enlargements of both groups. Student’s t-test. *P < 0.05, **P < 0.01, ***P < 0.001. Distribution of the various types of DElncRNAs. c Five classes (bidirectional lncRNAs, antisense lncRNAs, sense lncRNAs, intergenic lncRNAs and the other lncRNAs) were analyzed.
005988 might bind to some miRNAs according to the ceRNA analysis, which indicates its potential action as a ceRNA. Of course, additional in vivo and in vitro functional research is needed.

MRAK-159688, which was another up-regulated lncRNA identified in our study, is associated with the Fos gene and was named the Fos downstream transcript (FosDT) in a report from Mehta et al. [32]. Mehta et al. reported that, in an ischemia/reperfusion model, FosDT interacts with the chromatin-modifying proteins Sin3a and co-repressor of the transcription factor REST (coREST) and subsequently represses REST-downstream genes. Moreover, other researchers have indicated that MOR is one of the downstream targets of REST and is negatively modulated by REST in specific neuronal cells [33, 34]. Therefore, the dysregulated MRAK-159688 might be involved in the development of morphine tolerance through interactions with REST.

Since the ceRNA hypothesis was proposed, it has been verified in some tumor diseases. For example, the FER1L4/miRNA106a-5p/PTEN pathway constitutes a novel regulatory pathway that is involved in the occurrence and progression of gastric cancer [35]. Currently, ceRNA analysis is a novel method for predicting the functions of lncRNAs. In our study, we found that several possible interacting pathways among ceRNAs exist, including the following: MRAK161211, MRAK150340/miR-219b/mRNAs (e.g., Tollip, and Ubqln4); XR_
In our previous study, we have confirmed that miR-219-5p can attenuate morphine tolerance by targeting CaMKIIγ[12]. Furthermore, other researchers have also reported that miR-219 is down-regulated following the continuous application of morphine and can regulate NMDA receptor signaling[36]. Whereas in the present study, we predicted that miR-219b, rather than miR-219-5p, would exert this function. Recent research about miR-219 has mainly concentrated on the functions of miR-219-5p, and the other isoform, i.e., miR-219b, has not been studied in detail. However, on the one hand, we identified miR-219-5p and miR-219b, which have both previously been reported to function in the suppression of the proliferation, migration and invasion of cells[37, 38]. On the other hand, when we forecasted the downstream targets of miR-219b, we found that their functions were mainly related to the ubiquitination process, G-protein-coupled receptors, alterations in ion channels, and Toll-like receptor signaling pathway regulation, and these functions are all involved in the mechanisms of morphine tolerance. Therefore, given its possible target mRNAs, miR-219b is likely to be a new target related to morphine tolerance.

Toll-interacting protein (Tollip) is a potential downstream target of miR-219b and can modulate the expression of the Toll-like receptor (TLR) via its action as an

Fig. 4 ceRNA analyses indicated the potential lncRNA/miRNA/mRNA interactions. a The potential binding target miRNAs of the verified lncRNAs. The red nodes mean down-regulated lncRNAs, the gray nodes mean up-regulated lncRNAs, the blue squares mean down-regulated miRNAs we are interested in, the green squares mean up-regulated miRNA we are interested in, and the pink nodes mean the other miRNAs and mRNAs. b The lncRNA/miRNA/mRNA networks that we are interested in are displayed. The green nodes represent lncRNAs, the yellow pentagons represent miRNAs and the pink nodes represent mRNAs we forecasted.
endogenous inhibitor and regulate the IL-1β-induced activation of NF-κB; thus, miR-219b plays an inhibitory role in inflammatory signaling [39, 40]. Previous studies have demonstrated that the TLR-mediated activation of glial cells and TLR4-mediated NF-κB activation might influence the development of morphine tolerance [41, 42]. Therefore, further study is required and we presumed that the MRAK150340, MRAK161211 (i.e., downregulated IncRNAs)/miRNA-219b/Tollip interaction network potentially functions in morphine tolerance.

On the one hand, previous studies have suggested that let-7 can suppress the expression of MOR [43], and our previous results suggest miR-365 can modulate morphine tolerance by targeting the beta-arrestin 2 protein [11]. On the other hand, Law et al [44] reported that opioid receptor agonists (such as morphine) promote the ubiquitylation of scaffold proteins and thereby change the expression pattern of the receptor signaling pathway. In the present study, the potential downstream genes that we predicted, i.e., Usp31 and Usp42, are both ubiquitylation-related genes. Therefore, the XR_006440/(let7, miR-365)/(Usp31, Usp42) pathway is likely to be responsible for the formation of morphine tolerance. Moreover, there are other interested candidates other than the validated IncRNAs and mRNAs, and further studies will be needed.

In summary, although our study is preliminary and lacks additional functional experiments, our research has revealed that hundreds of IncRNAs, especially XR_005988 and MRAK159688, are differentially expressed in the spinal cords of morphine-tolerant rats. Further ceRNA analysis revealed that several possible IncRNA/miRNA/mRNA interaction networks exist, and among these networks, the (MRAK150340, MRAK161211)/miR-219b/Tollip network holds the most potential for further studies.

Abbreviations
cRNA: competitive endogenous; DEIncRNA: Differentially expressed IncRNA; DEMiRNA: Differentially expressed miRNA; GO: Gene Ontology; KEGG: Kyoto Encyclopedia of Genes and Genomes; IncRNA: Long noncoding RNA; MOR: μ-opioid receptor; MT: Morphine tolerance; NCBi: National Center for Biotechnology Information; ncRNA: Noncoding RNA; NS: Normal saline; Tollip: Toll-interacting protein

Funding
This work was supported by grants from the National Natural Science Foundation of China (81471135 and 81771206) and the Natural Science Funds for Distinguished Young Scholars of Hunan Province (2017JJ1036).

Availability of data and materials
Please contact author for data requests.

Authors’ contributions
WZ designed the experiments; JS, JW, JH, CL, YP and WZ performed experiments and analyzed data; JS, QG and WZ drafted the manuscript and finished the final version of the manuscript. All authors read and approved the final manuscript.

Ethics approval
All experiments were performed in accordance with the Animal Care and Use Committee of Central South University and the guidelines of the International Association for the Study of Pain.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 2 January 2018 Accepted: 4 April 2018
Published online: 10 April 2018

References
1. Ko SW, Wu LJ, Shum F, Quan J, Zhuo M. Cingulate NMDA NR2B receptors contribute to morphine-induced analgesic tolerance. Molecular brain. 2008;12. https://doi.org/10.1186/1756-6001-1-2.
2. Smith SMSM, Analgesic tolerance to opioids. Pain. 2001;9
3. Song Z, Guo Q, Zhang L, Guo Q, Zhou W. Proteomic analysis of PKGgamma-related proteins in the spinal cord of morphine-tolerant rats. PLoS One. 2012;7:e42068. https://doi.org/10.1371/journal.pone.0042068.
4. Song Z, Zou W, Liu C, Guo Q, Gene knockdown with lentiviral vector-mediated intrathecal RNA interference of protein kinase C gamma reverses chronic morphine tolerance in rats. The journal of gene medicine. 2010;12:873–80. https://doi.org/10.1002/jgm.1514.
5. Baii KK, Kuner R. Noncoding RNAs: key molecules in understanding and treating pain. Trends Mol Med. 2014;20:437–48. https://doi.org/10.1016/j.tolmed.2014.05.006.
6. Braïna Mattei Lutz AB, Tao Y-X. Noncoding RNAsnew players in chronic pain. Anesthesiology. 2014;121:409–17.
7. Hwang CK, Wagley Y, Law PY, Wei LN, Loh HH. MicroRNAs in opioid pharmacology. Journal of neuroimmune pharmacology : the official journal of the Society on Neuroimmune Pharmacology. 2012;7:808–19. https://doi.org/10.1007/s11481-011-9323-2.
8. Massimo Barbierato MZ, Staker SD, Giusti P. MicroRNAs: emerging role in the endogenous μ-opioid system. CNS Neural Disord Drug Targets. 2015;14:239–50.
9. Wu Q, Zhang L, Law PY. Long-term morphine treatment decreases the association of mu-opioid receptor (MOR1) mRNA with polysomes through miR23b. Mol Pharmacol. 2009;75:744–50. https://doi.org/10.1124/mol.108.05462.
10. Wu Q, Hwang CK, Zheng H, et al. MicroRNA 339 down-regulates mu-opioid receptor at the post-transcriptional level in response to opioid treatment. FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 2013;27:522–35. https://doi.org/10.1096/fj.12-213439.
11. Wang J, Xu W, Shao J, He Z, Ding Z, Huang J, Guo Q, Zou W. miR-365 targets beta-arrestin 2 to reverse morphine tolerance in rats. Sci Rep. 2016;6:38285. https://doi.org/10.1038/srep38285.
12. Wang J, Xu W, Shao J, He Z, Ding Z, Huang J, Guo Q, Zou W. miR-219-5p targets CaMKIgamma to attenuate morphine tolerance in rats. Oncotarget. 2017;8:28033–14. https://doi.org/10.18632/oncotarget.15997.
13. Brosnan CA, Voinnet O. The long and the short of noncoding RNAs. Curr Opin Cell Biol. 2009;21:416–25. https://doi.org/10.1016/j.cub.2009.04.001.
14. Wilusz JE, Sunwoo H, Spector DL. Long noncoding RNAs: functional surprises from the RNA world. Genes Dev. 2009;23:1494–504. https://doi.org/10.1101/gad.105193.109.
15. Yarmishyn AA, Kurochkin IV. Long noncoding RNAs: a potential novel class of cancer biomarkers. Front Genet. 2015;6:1–10. https://doi.org/10.3389/fgene.2015.00145.
16. Briggs JA, Wolvetang EJ, Mattick JS, et al. Mechanisms of long non-coding RNAs in mammalian nervous system development, plasticity, disease, and evolution. Neuron. 2015;88:861–77. https://doi.org/10.1016/j.neuron.2015.09.045.
17. Jiang SD, Lu J, Deng ZH, Li YS, Lei GH. Long noncoding RNAs in osteoarthritis. Joint, bone, spine : revue du rhumatisme. 2017;84:553–6. https://doi.org/10.1016/j.jspin.2016.09.006.
18. Zhao X, Tang Z, Zhang H, et al. A long noncoding RNA contributes to neuropathic pain by silencing Kcn2 in primary afferent neurons. Nat Neurosci. 2013;16:1024–31. https://doi.org/10.1038/nn.3438.

19. Wang S, Xu H, Zou L, Xie J, Wu H, Wu B, Yi Z, Lv Q, Zhang X, Ying M, Liu S, Li G, Gao Y, Xu C, Zhang C, Liang S. LncRNA uc.485 is involved in diabetic neuropathic pain mediated by the P2X3 receptor in the dorsal root ganglia. Mitochondrial signalling. 2016;12:139–48. https://doi.org/10.1007/s11302-015-9488-x.

20. Jiang BC, Sun WX, He LN, Cao DL, Zhang ZJ, Gao YJ. Identification of IncRNA expression profile in the spinal cord of mice following spinal nerve ligation-induced neuropathic pain. Mol Pain. 2015;11:43. https://doi.org/10.1186/s12980-015-0047-0.

21. Li G, Jiang H, Zhang C, Zhu G, Xu Y, Sheng X, Wu B, Guo J, Zhu S, Zhan Y, Lin W, Ding R, Zhang C, Liu S, Zou L, Yi Z, Liang S. Long noncoding RNA MRAK0099731 is a novel regulator of neuropathic pain in rats. Pain. 2017;158:2042–52. https://doi.org/10.1097/j.pain.000000000001013.

22. Peng H, Zou L, Xie J, Wu H, Wu B, Zhu G, Lv Q, Zhang X, Liu S, Li G, Xu H, Gao Y, Xu C, Zhang C, Wang S, Xue Y, Liang S. lncRNA NONRATT021724 sRNA decreases diabetic neuropathic pain mediated by the P2X3 receptor in dorsal root ganglia. Mol Neurobiol. 2017;54:511–23. https://doi.org/10.1007/s12052-015-9632-1.

23. Salmena L, Poliseno L, Tay Y, et al. A ceRNA hypothesis: the Rosetta stone of gene regulatory networks. Cell. 2011;146:353–67. https://doi.org/10.1016/j.cell.2011.07.014.

24. Tay Y, Rinn J, Pandolfi PP. The multilayered complexity of ceRNA crosstalk and competition. Nature. 2014;505:344–9. https://doi.org/10.1038/nature12986.

25. Zimmermann M. Ethical guidelines for investigations of experimental pain in conscious animals. Pain. 1983;16:109–10.

26. Wei Yu J-XH, Xiao-Jun X, et al. The development of morphine tolerance and dependence in rats with chronic pain. Brain Res. 1997;756:1-11. https://doi.org/10.1016/S0064-5278(97)00010-3.

27. Zou W, Song Z, Guo Q, Liu C, Zhang Z, Zhang Y. Intrathecal lentiviral-mediated RNA interference targeting PKCgamma attenuates chronic constriction injury-induced neuropathic pain in rats. Hum Gene Ther. 2011;22:6465–75. https://doi.org/10.1089/hum.2010.207.

28. Lin SP, Ye S, Long Y, et al. Circular RNA expression alterations are involved in OGD/R-induced neuron injury. Biochemical and biophysical research communications. 2016;471:52–6. https://doi.org/10.1016/j.bbrc.2016.01.183.

29. Jia H, Osak M, Bogu GK, Stanton LW, Johnson R, Lipovich L. Genome-wide computational identification and manual annotation of human long noncoding RNA genes. RNA. 2010;16:1478–87. https://doi.org/10.1261/rna.195130.109.

30. Huang JF, Guo YJ, Zhao CX, Yuan SX, Wang Y, Zhou WP, Sun SH. Hepatitis B virus X protein (HBx)-related long noncoding RNA (IncRNA) down-regulated expression by HBx (Dreh) inhibits hepatocellular carcinoma metastasis by targeting the intermediate filament protein vimentin. Hepatology. 2013;57:1882–92. https://doi.org/10.1002/hep.26195.

31. Derrien T, Johnson R, Bussotti G, et al. The GENCODE v7 catalog of human long noncoding RNAs: analysis of their gene structure, evolution, and expression. Genome Res. 2012;22:1775–89. https://doi.org/10.1101/gr.132159.111.

32. Mehta S, Kim T, Nemuganti R. Long Noncoding RNA FoxDT promotes ischemic brain injury by interacting with REST-associated chromatin-modifying proteins. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2015;35:16443–9. https://doi.org/10.1523/JNEUROSC12943-15.2015.

33. Kim CS, Hwang CK, Choi HS, et al. Neuron-restrictive silencer factor (NRSF) functions as a repressor in neuronal cells to regulate the opioid receptor gene. J Biol Chem. 2004;279:4646–73. https://doi.org/10.1074/jbc.M403633200.

34. Kim CS, Choi HS, Hwang CK, et al. Evidence of the neuron-restrictive silencer factor (NRSF) interaction with Sp3 and its synergetic repression to the mu opioid receptor (MOR) gene. Nucleic Acids Res. 2006;34:3932–403. https://doi.org/10.1093/nar/gkj724.

35. Xia T, Chen S, Jiang Z, et al. Long noncoding RNA FER1L4 suppresses cancer cell growth by acting as a competing endogenous RNA and regulating PTEN expression. Sci Rep. 2015;5: https://doi.org/10.1038/srep13445.

36. Kocerha J, Faghihi MA, Lopez-Toledano MA, et al. MicroRNA-219 modulates NMDA receptor-mediated neurobehavioral dysfunction. Proc Natl Acad Sci U S A. 2009;106:3507–12. https://doi.org/10.1073/pnas.0805854106.

37. Long JMQ, Wuren Q, et al. MiR-219-5p inhibits the growth and metastasis of malignant melanoma by targeting BCL-2. Biomed Res Int. 2017;2017:9035202. https://doi.org/10.1155/2017/9035202.

38. Zhao CLX, Han B, et al. Gga-miR-219b targeting BCL11B suppresses proliferation, migration and invasion of Marek’s disease tumor cell MSB1. Sci Rep. 2017;7:4247. https://doi.org/10.1038/s41598-017-04434-w.

39. Didierlaurent A, Brisoni B, Velin D, et al. Tollip regulates proinflammatory responses to interleukin-1 and lipopolysaccharide. Mol Cell Biol. 2006;26:735–42. https://doi.org/10.1128/MCB.26.3.735-742.2006.

40. Baccino DM. Tollip: a multitasking protein in innate immunity and protein trafficking. Microbes Infect. 2012;14:140–7. https://doi.org/10.1016/j.micinf.2011.08.018.

41. Hutchinson MB, Bland ST, Johnson KW, et al. Opioid-induced gial activation: mechanisms of activation and implications for opioid analgesia, dependence, and reward. TheScientificWorldJournal. 2007;7:98–111. https://doi.org/10.1100/tsw.2007.230.

42. Bai L, Zhai C, Han K, et al. Toll-like receptor 4-mediated nuclear factor-kappaB activation in spinal cord contributes to chronic morphine-induced analgesic tolerance and hyperalgesia in rats. Neuroscience bulletin. 2014;30:936–48. https://doi.org/10.1007/s12264-014-1483-7.

43. He Y, Wang ZJ. Let-7 microRNAs and opioid tolerance. Front Genet. 2012;3:1–7. https://doi.org/10.3389/fgene.2012.00110.

44. Law PR, Loh HH, Wei LN. Insights into the receptor transcription and signaling: implications in opioid tolerance and dependence. Neuropharmacology. 2004;47:300–11. https://doi.org/10.1016/j.neuropharm.2004.07.013.